

---

THE GENERAL ASSEMBLY OF PENNSYLVANIA

---

HOUSE BILL

No. 2006 Session of  
1995

---

INTRODUCED BY STURLA, VANCE, KUKOVICH, CAPPABIANCA, COY, KREBS,  
CLARK, ROEBUCK, DALEY, ROONEY, STABACK, LAUGHLIN, TIGUE,  
MELIO, BATTISTO, RAYMOND, ITKIN, HENNESSEY, READSHAW, STERN,  
BAKER, JOSEPHS, CURRY, MILLER, ZIMMERMAN, MIHALICH,  
RICHARDSON, TRELLO, SCHULER, DeLUCA, WOZNIAK, YOUNGBLOOD,  
STEELMAN, BOSCOLA AND BELFANTI, SEPTEMBER 20, 1995

---

REFERRED TO COMMITTEE ON HEALTH AND HUMAN SERVICES,  
SEPTEMBER 20, 1995

---

AN ACT

1 Providing options for blood transfusions to persons undergoing  
2 certain medical procedures; and further providing for duties  
3 of attending physicians, duties of health care facilities,  
4 duties of blood banks, disposal of blood and payment of  
5 service fees.

6 The General Assembly of the Commonwealth of Pennsylvania  
7 hereby enacts as follows:

8 Section 1. Short title.

9 This act shall be known and may be cited as the Blood Safety  
10 Act.

11 Section 2. Definitions.

12 The following words and phrases when used in this act shall  
13 have the meanings given to them in this section unless the  
14 context clearly indicates otherwise:

15 "Allogeneic blood." Blood that is donated on a voluntary  
16 basis without designating or knowing who the recipient is and  
17 which complies with all the requirements of the United States

1 Food and Drug Administration.

2 "Attending physician." The physician who is designated by  
3 the patient to perform a medical or surgical procedure.

4 "Autologous blood." Blood donated by a person for his own  
5 use.

6 "Biohazardous blood product." A blood product which has  
7 tested positive for one or more of the viral marker assays  
8 performed by licensed blood collectors.

9 "Blood." This term shall include blood components and whole  
10 blood.

11 "Blood bank." Any place, organization, institution or  
12 establishment that is operated wholly or in part for the purpose  
13 of obtaining, storing, processing, preparing for transfusing or  
14 selling human blood products derived from single blood units,  
15 whether such procedures are done for direct therapeutic use or  
16 for storage for future use of such products and whether such a  
17 place, organization, institution or establishment is operated on  
18 a charitable, commercial or nonprofit basis.

19 "Blood components." Any part or fraction of single units of  
20 whole blood or any material derived from single units of such  
21 blood, excluding albumin, rhogam and gammo globulin or other  
22 components which cannot transmit infectious agents.

23 "Department." The Department of Health of the Commonwealth.

24 "Designated blood." Blood donated for a specifically  
25 indicated recipient of the donated blood other than the donor  
26 and which complies with all the requirements of the United  
27 States Food and Drug Administration.

28 "Health care facility." A general or special hospital,  
29 including tuberculosis and psychiatric hospitals, rehabilitation  
30 facilities, skilled nursing facilities, kidney disease treatment

1 centers, including free-standing hemodialysis units,  
2 intermediate care facilities and ambulatory surgical facilities,  
3 both profit and nonprofit and including those operated by an  
4 agency of State or local government, but shall not include an  
5 office used exclusively for private or group practice by  
6 physicians or dentists, nor a program which renders treatment or  
7 care for drug or alcohol abuse or dependence, unless located  
8 within, by or through a health care facility, a facility  
9 providing treatment solely on the basis of prayer or spiritual  
10 means in accordance with the tenets of any church or religious  
11 denomination, nor a facility operated by a religious  
12 organization for the purpose of providing health care services  
13 exclusively to clergymen or other persons in a religious  
14 profession who are members of the religious denominations  
15 operating the facility.

16 "Informed consent." For the purposes of this act and of any  
17 proceedings arising under this act, the consent of a patient to  
18 the performance of health care services by a physician if, prior  
19 to consent having been given, the physician provided information  
20 to the patient about the proposed procedure, treatment or  
21 diagnosis that a reasonable patient would consider material to  
22 that decision whether or not to undergo the procedure or  
23 treatment.

24 "Transfusion." The act of transferring blood into the body  
25 of a person.

26 "Whole blood." The fluid that circulates in the heart,  
27 arteries, capillaries and veins of a human body carrying  
28 nourishment and oxygen to and bringing away waste products from  
29 all parts of the body.

30 Section 3. Duties of attending physicians.

1 (a) Informed consent.--Whenever it is anticipated that a  
2 transfusion may be necessary during a medical or surgical  
3 procedure, the attending physician shall, prior to performing a  
4 medical or surgical procedure, inform the patient or guardian or  
5 designated surrogate that a blood transfusion may be necessary  
6 during the procedure and of the options of predonating for  
7 autologous blood transfusions, receiving allogeneic blood  
8 transfusions or receiving designated blood transfusions, the  
9 risks and benefits of each of these alternatives and the risks  
10 of not receiving any transfusions if a transfusion becomes  
11 necessary and shall obtain the patient's informed consent in  
12 writing.

13 (b) Documentation.--The attending physician shall note on  
14 the patient's medical record, which shall be maintained in the  
15 office of the attending physician, that the patient or guardian  
16 or designated surrogate was advised of the opportunity to  
17 receive an autologous, allogeneic or designated blood  
18 transfusion, the risks of these alternatives and the risks of  
19 not receiving the transfusion if a transfusion becomes  
20 necessary.

21 (c) Predonation time.--If there are no medical  
22 contraindications or the medical or surgical procedure is not  
23 performed on an emergency basis, the attending physician shall  
24 allow adequate time, prior to the medical or surgical procedure,  
25 for predonation to occur.

26 (d) Waiver of predonation.--The patient or guardian or  
27 designated surrogate may waive the option to predonate  
28 autologous blood or have designated blood donated on his behalf.  
29 This waiver shall be in writing and made a part of the patient's  
30 record that is maintained in the office of the attending

1 physician. If the patient or guardian or designated surrogate  
2 waives the option to predonate autologous blood or have  
3 designated blood donated on his behalf, the attending physician  
4 shall not incur any liability for failure to allow predonation  
5 to occur.

6 Section 4. Duties of health care facilities.

7 (a) Option information.--All health care facilities shall  
8 assist, when possible, with the facilitation, promulgation and  
9 dissemination of information regarding the options available to  
10 a patient regarding the predonation of autologous blood,  
11 receiving allogeneic blood or receiving designated blood, the  
12 risks and benefits of each of these alternatives and the risks  
13 of not receiving any transfusion if a transfusion becomes  
14 necessary and shall obtain the patient's informed consent in  
15 writing.

16 (b) Documentation.--The health care facility shall note on  
17 the patient's record maintained at the facility as to whether  
18 the patient was informed by his attending physician of the blood  
19 transfusion options available. If the attending physician has  
20 failed to advise the patient of these options, the health care  
21 facility shall be responsible for advising the patient of these  
22 options, the risks and benefits of these alternatives and the  
23 risks of not receiving any transfusion if a transfusion becomes  
24 necessary and shall obtain the patient's informed consent in  
25 writing. The health care facility shall not incur any liability  
26 for failure to allow the predonation to occur if the patient has  
27 waived the option to predonate autologous blood or have  
28 designated blood donated on his behalf. This waiver shall be in  
29 writing.

30 (c) Acceptance of autologous or designated blood.--A health

1 care facility which performs a transfusion shall be required to  
2 accept autologous or designated blood for a potential  
3 transfusion to a patient if the blood meets the regulations of  
4 the United States Food and Drug Administration and is received  
5 from a blood bank located within this Commonwealth and licensed  
6 by the department. Autologous or designated blood which is  
7 received from a blood bank located outside this Commonwealth  
8 must be licensed by the state in which it is located and must  
9 also meet the regulations of the United States Food and Drug  
10 Administration. All autologous and designated blood must be  
11 tested and prepared in accordance with the standards approved by  
12 the department, except that autologous blood which is  
13 biohazardous may only be accepted with the written permission of  
14 the attending physician and the health care facility.

15 Section 5. Duties of blood banks.

16 (a) Option information.--All blood banks shall assist, when  
17 possible, with the facilitation, promulgation and dissemination  
18 of information regarding the options available to a patient  
19 regarding the predonation of autologous blood, receiving  
20 allogeneic blood or designated blood, the risks and benefits of  
21 each of these alternatives and the risks of not receiving any  
22 transfusion if a transfusion becomes necessary.

23 (b) Dissemination of information.--All blood banks shall  
24 assist with the facilitation, promulgation and dissemination of  
25 current information regarding the safety of available  
26 transfusion options to the medical community.

27 (c) Fees.--A blood bank which collects autologous or  
28 designated blood shall inform the donor of the blood or his  
29 guardian or designated surrogate or the intended recipient of  
30 the blood, in the case of a designated blood donation, of all

1 the fees that the blood bank charges to process, store,  
2 transport or otherwise prepare the blood for transfusion.

3 Section 6. Disposal of unused autologous and designated blood.

4 In cases where a medical or surgical procedure is performed  
5 and a transfusion was not performed or there is unused  
6 autologous or designated blood, that blood shall be held for a  
7 minimum of 21 days after the date of donation or a minimum of  
8 seven days after the date the procedure was performed or was  
9 scheduled to be performed for which the blood was originally  
10 donated, for possible use, unless the useful life of the blood  
11 has expired.

12 Section 7. Payment of service fee by health care facilities.

13 A health care facility which accepts autologous or designated  
14 blood and similar blood components shall pay a service fee to  
15 the blood bank which provides the blood or blood components.  
16 Insurance providers shall not deny payment of additional fees  
17 for autologous blood costs if allogeneic blood transfusions are  
18 covered in the policy. Any additional fees for designated blood  
19 over and above allogeneic blood fees, unless medically  
20 indicated, may be rejected for payment unless otherwise covered  
21 in the policy.

22 Section 8. Exemptions.

23 The attending physician or the health care facility where the  
24 medical or surgical procedure is to be performed shall not be  
25 required to provide the patient or his guardian or designated  
26 surrogate with an explanation of the transfusion options under  
27 this act if medical contraindications exist or the medical or  
28 surgical procedure is performed on an emergency basis.

29 Section 9. Liability.

30 No physician shall be liable for a failure to obtain an

1 informed consent in the event of an emergency which prevents  
2 consulting the patient. No physician shall be liable for failure  
3 to obtain an informed consent if it is established by a  
4 preponderance of the evidence that furnishing the information in  
5 question to the patient would have resulted in a seriously  
6 adverse effect on the patient or on the therapeutic process to  
7 the material detriment of the patient's health.

8 Section 10. Effective date.

9 This act shall take effect in 60 days.